cell_type

Microglia

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Microglia: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

10678Connections

30Hypotheses

30Analyses

50Outgoing

50Incoming

Summary

Microglia is a cell type relevant to neurodegeneration research. Key relationships include: expressed in, involved in, associated with. Associated with Alzheimer's Disease, Amyloidosis, Amyotrophic Lateral Sclerosis. Connected to 313 entities in the SciDEX knowledge graph.

View on Wiki →

🧫 Cell Type Info

Cell Type	Microglia
Associated Diseases	Alzheimer's Disease, Amyloidosis, Amyotrophic Lateral Sclerosis, Cardiovascular Diseases, Chronic Traumatic Encephalopathy
Related Genes	SNCA, TNF-Α
Linked Hypotheses	176 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

→

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

→

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

→

Pathway Diagram

flowchart TD
    MICROGLIA(["MICROGLIA"])
    NEUROINFLAMMATION(["NEUROINFLAMMATION"])
    NEURON(["NEURON"])
    TAU(["TAU"])
    NEURODEGENERATION(["NEURODEGENERATION"])
    Neurodegeneration["Neurodegeneration"]
    Alzheimer["Alzheimer"]
    Als["Als"]
    Parkinson["Parkinson"]
    Neuroinflammation["Neuroinflammation"]
    Inflammation["Inflammation"]
    Toll_Like_Receptor["Toll-Like Receptor"]

    MICROGLIA -->|"associated with"| NEUROINFLAMMATION
    MICROGLIA -->|"associated with"| NEURON
    MICROGLIA -->|"associated with"| TAU
    MICROGLIA -->|"associated with"| NEURODEGENERATION
    MICROGLIA -->|"associated with"| Neurodegeneration
    MICROGLIA -->|"regulates"| Alzheimer
    MICROGLIA -->|"regulates"| Als
    MICROGLIA -->|"regulates"| Neurodegeneration
    MICROGLIA -->|"activates"| NEUROINFLAMMATION
    MICROGLIA -->|"activates"| Parkinson
    MICROGLIA -->|"activates"| Neuroinflammation
    MICROGLIA -->|"activates"| Inflammation
    MICROGLIA -->|"activates"| Toll_Like_Receptor
    MICROGLIA -->|"activates"| NEURODEGENERATION
    MICROGLIA -->|"activates"| Alzheimer

    style MICROGLIA fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (4793)

Target	Relation	Type	Str
Amyloid-Beta Deposits	degrades	structure	0.98
Brain Homeostasis	associated_with	process	0.95
Neurodegeneration	involved_in	process	0.95
Synaptic Plasticity	regulates	process	0.95
Learning and Memory	regulates	process	0.95
SNCA	cleaves	protein	0.95
Synucleinphagy	involved_in	process	0.95
Neurodegeneration	protects_against	disease	0.95
Synaptic Pruning	mediates	process	0.95
Synapse Loss	mediates	phenotype	0.95
TNF-Α	associated_with	protein	0.95
Central Nervous System	expressed_in	process	0.95
Neuronal Death	causes	process	0.95
Yolk Sac Precursors	product_of	cell_type	0.95
Neuroinflammation	contributes_to	process	0.95
TREM2	expressed_in	gene	0.95
Pro-inflammatory Factors	mediates	process	0.95
Neuronal Autophagy	inhibits	process	0.95
Ferroptosis	involved_in	process	0.95
T Cell Infiltration	mediates	process	0.95
Alzheimer Disease	contributes_to	disease	0.95
Glucose Metabolic Reprogramming	involved_in	process	0.95
Synapse Remodeling	mediates	process	0.95
Neuroinflammation	modulates	process	0.95
Alzheimer's Disease	causes	disease	0.95
Amyloid-Beta Clearance	mediates	process	0.95
Glucose Metabolism	regulates	pathway	0.95
SNCA	degrades	protein	0.95
Glucose Metabolism	involved_in	pathway	0.95
Post-Stroke Inflammation	involved_in	process	0.95
NLRP3	expressed_in	protein	0.95
NEUROINFLAMMATION	mediates	process	0.95
Synaptic Remodeling	mediates	process	0.95
Extracellular Matrix	degrades	structure	0.95
Aβ42	associated_with	protein	0.95
Phagocytosis	mediates	process	0.95
Aβ42 Fibrils	associated_with	compound	0.95
Inhibitory Synapses	mediates	structure	0.94
Learning And Memory	regulates	phenotype	0.92
Astrocyte-Synapse Contact	regulates	process	0.92
Oxidative Stress Response	involved_in	process	0.91
Glucose Metabolism	associated_with	process	0.90
Alzheimer's Disease	involved_in	disease	0.90
Parkinson's Disease	involved_in	disease	0.90
Amyotrophic Lateral Sclerosis	involved_in	disease	0.90
Multiple Sclerosis	involved_in	disease	0.90
Synapses	associated_with	cell_type	0.90
Synaptic Elimination	involved_in	process	0.90
Neuroprotection	mediates	process	0.90
Alzheimer's Disease	associated_with	disease	0.90

Incoming (5885)

Source	Relation	Type	Str
Β-Hydroxybutyrate	regulates	compound	0.98
Dam	component_of	cell_type	0.95
CD22	expressed_in	receptor	0.95
CD22	modulates	receptor	0.95
Inflammasome	activates	process	0.95
NLRP3 INFLAMMASOME	activates	protein	0.95
IFI27L2A	expressed_in	gene	0.95
Microglial Pyroptosis	associated_with	process	0.95
AMYLOID BETA	activates	protein	0.95
OLFML3	expressed_in	protein	0.95
Hemichannel Blockade	modulates	mechanism	0.95
TIM-3	expressed_in	protein	0.95
P2X7R	expressed_in	receptor	0.95
Trem2-Apoe Pathway	regulates	pathway	0.95
IL4	activates	entity	0.95
α-synuclein	activates	protein	0.95
Alzheimer'S Disease	associated_with	disease	0.95
CSF1R Inhibition	modulates	mechanism	0.95
IL33R	expressed_in	receptor	0.95
IPA	modulates	compound	0.95
SNCA	interacts_with	protein	0.94
APOB	binds	protein	0.93
Yolk Sac Precursors	product_of	cell_type	0.92
SPP1	modulates	protein	0.92
CD2AP	expressed_in	protein	0.92
Glycometabolic Reprogramming	modulates	process	0.92
Extracellular Vesicles	interacts_with	compound	0.92
Connexin43 Hemichannel Blockade	modulates	mechanism	0.90
Perivascular Cells	modulates	cell_type	0.90
KV1.3	expressed_in	protein	0.90
SNCA	activates	protein	0.90
NPTX2	modulates	protein	0.90
Iba1	biomarker_for	biomarker	0.90
TREM2-APOE Pathway	modulates	pathway	0.90
MNPs@FMN	targets	drug	0.90
Alzheimer's Disease	associated_with	disease	0.90
Act001	modulates	compound	0.90
Iron Accumulation	modulates	process	0.90
FPR1	expressed_in	receptor	0.90
Iron Overload	associated_with	phenotype	0.90
Iron	associated_with	compound	0.90
CX3CL1	interacts_with	protein	0.90
Polystyrene Nanoplastics	activates	compound	0.90
Minocycline	inhibits	drug	0.90
SPI1	expressed_in	gene	0.90
Glycometabolic Reprogramming	involved_in	process	0.90
Astrocyte	interacts_with	cell_type	0.90
Ros	activates	process	0.90
NLRP3 Inflammasome	activates	pathway	0.90
Perivascular Cells	activates	cell_type	0.90

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TREM2-Dependent Microglial Senescence Transition	0.692	neurodegeneration	Gene expression changes in aging mouse b
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro	0.662	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen	0.639	neurodegeneration	Gene expression changes in aging mouse b
SASP-Driven Microglial Metabolic Reprogramming in Synaptic P	0.638	neurodegeneration	Senolytic therapy for age-related neurod
TREM2-Dependent Microglial Phagocytosis Acts as a Strain Sel	0.636	neurodegeneration	What are the specific molecular determin

IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microgl	0.632	neuroinflammation	How do oligodendrocytes initiate neuroin
Microglial TREM2-SYK Pathway Enhancement	0.626	neurodegeneration	Cell type vulnerability in Alzheimers Di
Prime Editing Precision Correction of APOE4 to APOE3 in Micr	0.622	neurodegeneration	CRISPR-based therapeutic approaches for
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene	0.612	neurodegeneration	Gene expression changes in aging mouse b
TREM2-ASM Crosstalk in Microglial Lysosomal Senescence	0.612	neurodegeneration	Gene expression changes in aging mouse b
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener	0.607	neurodegeneration	Gene expression changes in aging mouse b
TREM2-Microglial Clearance Enhancement as Common Mechanism f	0.604	neurodegeneration	Why do p300/CBP inhibitors reduce both A
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43	0.601	neurodegeneration	What are the mechanisms by which gut mic
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc	0.600	neurodegeneration	Gene expression changes in aging mouse b
C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward	0.596	neuroinflammation	What molecular mechanisms determine whet
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.589	neurodegeneration	Gene expression changes in aging mouse b
H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from	0.588	neurodegeneration	How does APOE4's beneficial immune funct
Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senesc	0.587	neuroinflammation	What molecular mechanisms drive the tran
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging	0.587	neurodegeneration	Gene expression changes in aging mouse b
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene	0.585	neurodegeneration	Gene expression changes in aging mouse b
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene	0.580	neurodegeneration	Gene expression changes in aging mouse b
TREM2-Mediated Cholesterol Dysregulation in Microglial Senes	0.574	neurodegeneration	Gene expression changes in aging mouse b
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli	0.569	neurodegeneration	Lipid raft composition changes in synapt
Targeted Butyrate Supplementation for Microglial Phenotype M	0.559	neurodegeneration	What are the mechanisms by which gut mic
Senescent Microglia Resolution via Maresins-Senolytics Combi	0.552	neurodegeneration	Neuroinflammation resolution mechanisms
ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling	0.538	neurodegeneration	Why does the V1613M variant reduce amylo
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign	0.533	neuroscience	Circuit-level neural dynamics in neurode
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular	0.527	neuroscience	Circuit-level neural dynamics in neurode
Microglial TREM2-Complement Axis Modulation	0.527	neurodegeneration	Cell type vulnerability in Alzheimer's D
TREM2 Agonism to Redirect Microglia from Synaptic Pruning to	0.521	neurodegeneration	How do ALS-associated OPTN mutations mec

Mentioning Analyses (30)

Scientific analyses that reference this entity

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214]	Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia	J Inflamm Res	2022	1
TREM2, microglia, and Alzheimer's disease. [PMID:33516818]	Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang	Mech Ageing Dev	2021	1
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2- [PMID:31932797]	Zhou Y, Song WM, Andhey PS, Swain A, Lev	Nat Med	2020	1
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. [PMID:28802038]	Ulland TK, Song WM, Huang SC, Ulrich JD,	Cell	2017	1
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663]	Krasemann S, Madore C, Cialic R, Baufeld	Immunity	2017	1
Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emergi [PMID:41772271]	Mushtaq T, Hameed H, Khan MA, Tariq U, H	Molecular neurobiology	2026	0
Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardi [PMID:41276911]	Wang L, Tao X, Zhang N, Yang X, Jiang H	Adv Sci (Weinh)	2026	0
APOE Genotype Modulates the Relationship of Stroke With Dementia Risk: Associati [PMID:41404739]	Zhang CH, Huang LY, Feng YG, Tan CC, Tan	J Am Heart Assoc	2026	0
High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence Fro [PMID:41406402]	Du Y, Borné Y, Samuelsson J, Glans I, Hu	Neurology	2026	0
Prime Editing of Alzheimer's Disease High-Risk APOE4 Allele by Brain-Directed Ad [PMID:41449667]	Günaydin C, Hackett NR, Wakim V, Sondhi	Hum Gene Ther	2026	0
The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and [PMID:41527736]	Abedin MJ, Kastanenka KV	J Alzheimers Dis	2026	0
Endothelial TBK1 Deficiency Inhibits Endothelial-to-Mesenchymal Transition and A [PMID:41685426]	Pu Y, Dong P, He L, Huang J, Wu Y et al.	Circ Res	2026	0
Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differe [PMID:41692246]	Strickland MR, Wang Z, Golden LR, Wang H	J Lipid Res	2026	0
Protective mutations associated with APOE in Alzheimer's disease. [PMID:41703264]	Ma Y, Li Y, Wu G, Liu L, Tian M et al.	Mol Psychiatry	2026	0
HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair. [PMID:41932381]	Hjæresen S, Gramkow ET, Zhang M, Svennin	Prog Neurobiol	2026	0
Trajectories of frailty, grip strength and gait speed preceding dementia: a nest [PMID:41936045]	Wu Z, Phyo AZZ, Cribb L, Vishwanath S, O	Age Ageing	2026	0
Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's dise [PMID:41936348]	Shimasaki R, Kurihara M, Bannai T, Hatan	J Prev Alzheimers Dis	2026	0
Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical p [PMID:41940854]	Alcalá Ramírez Del Puerto JM, Ortega-Mad	J Alzheimers Dis	2026	0
Opposing patterns of blood-brain barrier permeability and Alzheimer's disease bi [PMID:41942760]	Bernocchi F, Bonomi CG, Poli M, Di Donna	Neurological sciences : offici	2026	0
Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating s [PMID:41943971]	Aracki-Trenkic A, Živanović M, Milošević	Biomol Biomed	2026	0

Microglia

Understanding Entity Pages

Summary

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Sleep and Circadian Dysfunction in Alzheimer's Disease

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

Parthanatos in Neurodegeneration

CBS/PSP Rehabilitation Master Guide

calcium-dysregulation-comparison

Alpha-Synuclein Pathology

Alzheimer's Disease Mechanism Index

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

Pathway Diagram

Outgoing (4793)

Incoming (5885)

Targeting Hypotheses (30)

Mentioning Analyses (30)

What molecular mechanisms mediate SPP1-induced microglial phagocytic activation

What is the temporal sequence of TREM2 signaling transition from protective to i

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

What signals trigger microglia to specifically recognize and phagocytose LC axon

What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodege

How do oligodendrocytes initiate neuroinflammation in PD when microglia are trad

How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis c

What are the molecular signatures that distinguish protective vs. harmful microg

Can P16INK4A expression reliably distinguish harmful from beneficial senescent m

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

What brain concentrations of SCFAs are achieved via oral probiotics and are they

What distinguishes truly senescent brain cells from merely dysfunctional reactiv

Can circadian interventions selectively target microglia without affecting other

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

Why does prolonged anesthesia cause both cognitive dysfunction and anxiety throu

How does SPI1 transcriptionally regulate C1QA and C1QC expression in atheroscler

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

Do different priming stimuli require distinct therapeutic approaches or share co

Can circadian interventions reverse microglial priming independent of sleep disr

How can CNS-selective HDAC/DNMT inhibitors be developed to avoid systemic toxici

What specific astrocyte-derived factors can 'erase' pathological microglial memo

How does sevoflurane-induced NF-κB activation specifically trigger complement ca

What determines the selectivity of complement-mediated synaptic elimination in p

Do perinatal immune challenges create persistent epigenetic modifications that p

What causes IBA1 low/negative microglia in liver disease and how does this affec

What is the optimal therapeutic window during preclinical AD for epigenetic repr

Do microglia actually switch between glycolytic and oxidative phosphorylation as

How does P2RY12-mediated VSMC dysfunction contribute to cerebrovascular neurodeg

Does SPP1-mediated synaptic engulfment represent beneficial clearance or patholo

How do perivascular cells specifically recognize and respond to amyloid-β to upr

Related Papers (20)